DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE Mkt: NAVB), a specialty pharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that clinical data comparing its amyloid imaging candidate, AZD4694, to the benchmark amyloid imaging agent, 11C-PIB, was presented at the Society of Nuclear Medicine Annual Meeting in Miami, Florida.
